Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases.

Hélène Maillard-Lefebvre, Eric Boulanger, Maïté Daroux, Cédric Gaxatte, Barry Hudson, Marc Lambert

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

The formation of advanced glycation end products (AGEs) is a result of the non-enzymatic reaction between sugars and free amino groups of proteins. AGEs, through interacting with their specific receptor for AGEs (RAGE), result in activation of pro-inflammatory states and are involved in numerous pathologic situations. The soluble form of RAGE (sRAGE) is able to act as a decoy to avoid interaction of RAGE with its pro-inflammatory ligands (AGEs, HMGB1, S100 proteins). sRAGE levels have been found to be decreased in chronic inflammatory diseases including atherosclerosis, diabetes, renal failure and the aging process. The use of measuring circulating sRAGEs may prove to be a valuable vascular biomarker and in this review, we describe the implications of sRAGE in inflammation and propose that this molecule may represent a future therapeutic target in chronic inflammatory diseases.

Original languageEnglish
Pages (from-to)1190-1196
Number of pages7
JournalRheumatology (Oxford, England)
Volume48
Issue number10
StatePublished - Oct 1 2009
Externally publishedYes

Fingerprint

Chronic Disease
Biomarkers
HMGB1 Protein
Amino Sugars
Advanced Glycosylation End Products
S100 Proteins
Renal Insufficiency
Blood Vessels
Atherosclerosis
Ligands
Inflammation
Advanced Glycosylation End Product-Specific Receptor
Proteins
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Soluble receptor for advanced glycation end products : a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. / Maillard-Lefebvre, Hélène; Boulanger, Eric; Daroux, Maïté; Gaxatte, Cédric; Hudson, Barry; Lambert, Marc.

In: Rheumatology (Oxford, England), Vol. 48, No. 10, 01.10.2009, p. 1190-1196.

Research output: Contribution to journalArticle

Maillard-Lefebvre, H, Boulanger, E, Daroux, M, Gaxatte, C, Hudson, B & Lambert, M 2009, 'Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases.', Rheumatology (Oxford, England), vol. 48, no. 10, pp. 1190-1196.
Maillard-Lefebvre, Hélène ; Boulanger, Eric ; Daroux, Maïté ; Gaxatte, Cédric ; Hudson, Barry ; Lambert, Marc. / Soluble receptor for advanced glycation end products : a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. In: Rheumatology (Oxford, England). 2009 ; Vol. 48, No. 10. pp. 1190-1196.
@article{1fb7f35606f945719370c9470c98adff,
title = "Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases.",
abstract = "The formation of advanced glycation end products (AGEs) is a result of the non-enzymatic reaction between sugars and free amino groups of proteins. AGEs, through interacting with their specific receptor for AGEs (RAGE), result in activation of pro-inflammatory states and are involved in numerous pathologic situations. The soluble form of RAGE (sRAGE) is able to act as a decoy to avoid interaction of RAGE with its pro-inflammatory ligands (AGEs, HMGB1, S100 proteins). sRAGE levels have been found to be decreased in chronic inflammatory diseases including atherosclerosis, diabetes, renal failure and the aging process. The use of measuring circulating sRAGEs may prove to be a valuable vascular biomarker and in this review, we describe the implications of sRAGE in inflammation and propose that this molecule may represent a future therapeutic target in chronic inflammatory diseases.",
author = "H{\'e}l{\`e}ne Maillard-Lefebvre and Eric Boulanger and Ma{\"i}t{\'e} Daroux and C{\'e}dric Gaxatte and Barry Hudson and Marc Lambert",
year = "2009",
month = "10",
day = "1",
language = "English",
volume = "48",
pages = "1190--1196",
journal = "Rheumatology (United Kingdom)",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Soluble receptor for advanced glycation end products

T2 - a new biomarker in diagnosis and prognosis of chronic inflammatory diseases.

AU - Maillard-Lefebvre, Hélène

AU - Boulanger, Eric

AU - Daroux, Maïté

AU - Gaxatte, Cédric

AU - Hudson, Barry

AU - Lambert, Marc

PY - 2009/10/1

Y1 - 2009/10/1

N2 - The formation of advanced glycation end products (AGEs) is a result of the non-enzymatic reaction between sugars and free amino groups of proteins. AGEs, through interacting with their specific receptor for AGEs (RAGE), result in activation of pro-inflammatory states and are involved in numerous pathologic situations. The soluble form of RAGE (sRAGE) is able to act as a decoy to avoid interaction of RAGE with its pro-inflammatory ligands (AGEs, HMGB1, S100 proteins). sRAGE levels have been found to be decreased in chronic inflammatory diseases including atherosclerosis, diabetes, renal failure and the aging process. The use of measuring circulating sRAGEs may prove to be a valuable vascular biomarker and in this review, we describe the implications of sRAGE in inflammation and propose that this molecule may represent a future therapeutic target in chronic inflammatory diseases.

AB - The formation of advanced glycation end products (AGEs) is a result of the non-enzymatic reaction between sugars and free amino groups of proteins. AGEs, through interacting with their specific receptor for AGEs (RAGE), result in activation of pro-inflammatory states and are involved in numerous pathologic situations. The soluble form of RAGE (sRAGE) is able to act as a decoy to avoid interaction of RAGE with its pro-inflammatory ligands (AGEs, HMGB1, S100 proteins). sRAGE levels have been found to be decreased in chronic inflammatory diseases including atherosclerosis, diabetes, renal failure and the aging process. The use of measuring circulating sRAGEs may prove to be a valuable vascular biomarker and in this review, we describe the implications of sRAGE in inflammation and propose that this molecule may represent a future therapeutic target in chronic inflammatory diseases.

UR - http://www.scopus.com/inward/record.url?scp=70350774161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350774161&partnerID=8YFLogxK

M3 - Article

C2 - 19589888

AN - SCOPUS:70350774161

VL - 48

SP - 1190

EP - 1196

JO - Rheumatology (United Kingdom)

JF - Rheumatology (United Kingdom)

SN - 1462-0324

IS - 10

ER -